FGFR2 and cholangiocarcinoma: In other advanced/metastatic FGFR2 fusion or rearrangement-positive cholangiocarcinoma studies, pemigatinib reported a median PFS of 6.9 months (95% CI, 6.2–9.6) and OS of 21.1 months (95% CI, 14.8–NE) [10], infigratinib reported a median PFS of 7.3 months (95% CI, 5.6 − 7.6) and OS of 12.2 months (95% CI, 10.7 − 14.9) [12], and futibatinib reported a median PFS of 5.1 months (95% CI, 3.7–9.0) [13].